Quectel Releases New 4G/5G, LPWA and GNSS Antennas to Help Customers Optimize Device Performance
11.7.2023 12:00:00 EEST | Business Wire | Press release
Quectel Wireless Solutions, an IoT global solutions provider, proudly announces the launch of an exciting line-up of antennas designed to meet a wide spectrum of requirements:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230711943901/en/
Quectel releases new 4G/5G, LPWA and GNSS antennas to help customers optimize device performance (Photo: Business Wire)
- YEMN926J1A: This state-of-the-art 9-in-1 5G screw mount combo antenna is at the forefront of technology. It offers superior performance for 5G networks and is designed with a screw mount for easy installation.
- YECW000N1A: This external antenna is specifically optimized for low power wide area (LPWA) networks. It provides excellent connectivity for LPWA applications and ensures reliable and efficient communication.
- YEGT000W8A: Our advanced active global satellite navigation system (GNSS) L1 and L5 antenna, ideal for precise positioning and timing. It offers enhanced accuracy and reliability for GNSS applications.
These antennas showcase cutting-edge technology and are designed to meet the demands of today's connectivity requirements.
“We’re proud to launch these three new antennas which further add to our range of 4G/5G, LPWA and GNSS antennas,” said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “Antennas are often overlooked during device development but it’s important to enable developers with antennas that can be optimized for their specific use cases and provide them with the performance they need to meet their application needs. These new antennas provide customers with even greater opportunities to optimize their solutions as they build a smarter world.”
The YEMN926J1A is a 9-in-1 5G screw mount combo antenna optimized for 5G and 4G networks. It includes a GNSS antenna and measures 167mm x 57mm. Both RoHS and REACH compliant, the combo antenna also is IP67 and IP69K rated which means it offers complete protection against ingress of dust and airborne particles as well as protection against water and liquids up to and including immersion in up to 1m of water. The IP69K rating also means the product can withstand washdown pressure of 80-100 bar in phases of 14-16 l/min at temperatures of up to 80°C.
The ultra-wide-band 5G/4G antenna box provides broad coverage from 600-6,000MHz while offering support for 3G and 2G networks as well at Cat-M and NB-IoT. The antenna is designed to work with various ground plane sizes or in free space for ease of integration with nine cable connections on the antenna as required and cable length options from 300mm to 5000mm, terminated with SMA connectors. The screw mount omnidirectional antenna is easy to install with maximized durability and is compatible with Quectel's RM520x series modules.
The YECW000N1A external antenna offers high efficiency with a low profile and is optimized for LPWA connections. With dimensions of 149.73mm x 49.91mm x 35.5mm, the antenna operates in the 450-470MHz, 700-960MHz and 1710-2690MHz frequency bands. The external 4G antenna covers the main LTE bands and is also compatible with 3G, 2G and LPWA bands.
RoHS compliant, the YECW000N1A has been carefully designed so it is minimally influenced by the internal environment of devices it is connected to. This enables it to deliver better efficiency, radiation and gain while providing optimized performance for customers’ products. A further advantage is that Quectel offers flexible installation options with custom cable lengths and connectors available.
Completing Quectel’s latest antenna introductions, the YEGT000W8A is an active GNSS L1 and L5 antenna that supports the 1164-1189MHz and 1559-1606MHz frequency bands. With dimensions of 65mm x 45mm, the GNSS antenna is RoHS and IP67 compliant.
The YEGT000W8A offers a choice of configurations to guarantee the most suitable polarization type and was specifically developed for 5G RAN timing. Quectel’s positioning products support single-band or multi-band operation modes to meet various high- precision positioning requirements of customers’ products. Customized connector types and cable lengths are provided according to customers’ requirements.
In addition to providing antennas, Quectel also provides comprehensive antenna design support which includes simulation, testing and manufacturing for custom antenna solutions to meet customers’ specific application needs. This support, allied to innovative antennas, helps enable customers to optimize device performance.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas, services and IoT connectivity.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230711943901/en/
Contact information
Media: media@quectel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom